SCD and esophageal squamous cell carcinoma: In preclinical studies, inhibiting SCD1 with MF-438 has been shown to reverse resistance to cisplatin in non-small lung cancer stem cell lines and increase the effectiveness of radiation therapy in esophageal squamous cell carcinoma cell lines [43,44].